An international study designed to answer reliably whether, for women who have hormone sensitive early breast cancer (the most common type of breast cancer), 10 years of adjuvant tamoxifen (a hormone treatment) confers more benefit than just 5 years in terms of reducing the risk of relapse and improving overall, long-term survival: Adjuvant Tamoxifen - Longer Against Shorter (ATLAS)

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2012
This article has no abstract
Epistemonikos ID: 2484bc39ef2baf6f5d470f855bb3e10c678bbe8d
First added on: Jan 17, 2025